Boehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, as price competition began to affect its biggest selling drug Spiriva. The German pharma's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback